DOP47 The changing pattern of inflammatory bowel disease incidence in Northern France: A continuing increase in the young women (1988–2014)
ECCO'20 Vienna
2020
DOP48 Gene expression landscape of epithelial monolayer in inflammatory bowel disease
ECCO'20 Vienna
2020
DOP49 Quantitative proteomics analysis of macrophages from Crohn’s disease patients and infected with adherent-invasive Escherichia coli
ECCO'20 Vienna
2020
DOP51 Investigation on the role of Par4-associated cell polarity and associated barrier defects in inflammatory bowel diseases
ECCO'20 Vienna
2020
DOP54 Integrated network analysis using patient-specific single-nucleotide polymorphism profiles uncovers new pathways involved in ulcerative colitis pathogenesis
ECCO'20 Vienna
2020
DOP57 Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicentre, retrospective case–control study
ECCO'20 Vienna
2020
DOP58 Tofacitinib for ulcerative colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
ECCO'20 Vienna
2020
DOP60 Vedolizumab treatment persistence and safety in an extended access program (XAP)
ECCO'20 Vienna
2020
DOP62 Morbidity after primary ileocecal resection for Crohn’s disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centre
ECCO'20 Vienna
2020
DOP63 Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with inflammatory bowel disease: a randomised controlled trial
ECCO'20 Vienna
2020
DOP64 Discovery of highly selective small-molecule oral inhibitors of integrin α4β7 for the treatment of inflammatory bowel diseases
ECCO'20 Vienna
2020